Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Francini, Filippo, Pascucci, Alessandra, Francini, Edoardo, Bargagli, Gianluca, Conca, Raffaele, Licchetta, Antonella, Roviello, Giandomenico, Martellucci, Ignazio, Chiriacò, Giorgio, Miano, Salvatora Tindara, Marzocca, Giuseppe, Manganelli, Antonio, Ponchietti, Roberto, Savelli, Vinno, Petrioli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200276/
https://www.ncbi.nlm.nih.gov/pubmed/22096653
http://dx.doi.org/10.1155/2011/258689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200276/
https://www.ncbi.nlm.nih.gov/pubmed/22096653
http://dx.doi.org/10.1155/2011/258689

Ejemplares similares